PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 160 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following... December 3, 2025 COVID-19 Vaccine Myth Busters January 28, 2021 Single Mom Has To Beg For Rides To Doctor For Son... March 14, 2019 Load more HOT NEWS Our new strategy to make discoveries, drive progress, and bring hope Mississippi Teen Uses Make-A-Wish Grant To Feed Homeless In His Community Melanoma Cells Are More Likely to Spread after a Stopover in... How to Find a Caregiver When You Have Cancer
